登录新浪财经APP 搜索【信披】查看更多考评等级 安徽中电鑫龙科技股份有限公司（以下简称"公司"或"本公司"）股票交易价格连续3个交易日（2025年8 月15日、8月18日、8月19日）收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规则》等 有关规定，属于股票交易异常波动的情形。 二、公司关注、核实情况说明 针对公司股票异常波动，公司董事会对有关事项进行了核实，有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司目前经营情况正常，不存在内外部经营环境发生重大变化的情形； 3、公司及控股股东、实际控制人不存在关于公司的应披露而未披露的重大事项，或处于筹划阶段的重 大事项； 4、经核查，控股股东、实际控制人在公司股票交易异常波动期间不存在买卖公司股票的行为； 5、经自查，公司不存在违反公平信息披露规定的其他情形。 公司董事会全体董事保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 公司董事会确认，公司目前没有根据《深圳证券交易所股票上市规则》等有关规定应予以披露而未披露 的事项或与该事项有关的筹划、商谈、意向、协议等；董事会也未获 ...

Core Viewpoint - Oulin Bio (688319) experienced a significant stock price increase, with a cumulative rise of over 30% in three consecutive trading days, leading to a classification of abnormal trading activity [1] Company Summary - Oulin Bio confirmed that its daily operations are normal and there have been no significant changes in its business [1] - The company conducted inquiries with its controlling shareholder and actual controller, confirming that there are no undisclosed major information as of the announcement date [1] - The recent stock price increase of Oulin Bio has outpaced most of its industry peers and the Shanghai Composite Index, indicating a potential short-term market overheating risk [1]

Core Viewpoint - *ST Songfa's stock price has experienced significant fluctuations, with a cumulative increase of 15.3% over three trading days, contrasting with the market's 1.88% rise, indicating potential investor interest and market volatility [1] Group 1: Stock Performance - The stock price of *ST Songfa increased by 15.3% from August 18 to August 20, while the overall market rose by 1.88% during the same period [1] - As of the close on August 20, *ST Songfa's stock was priced at 59.3 yuan per share, resulting in a total market capitalization of 575.7 billion yuan [1] Group 2: Company Announcements - The company disclosed that it has not identified any undisclosed significant information aside from what has already been made public [1] - *ST Songfa has undergone a major asset restructuring, with the completion of related transactions expected by May 2025 and the registration of new shares by August 18, 2025 [1] Group 3: Business Transformation - The company's main business has shifted from ceramic manufacturing to the research, development, production, and sales of ships and high-end equipment [1]

芯原股份8月20日公告，公司股票交易连续三个交易日内收盘价格涨幅偏离值累计超过30%，属于股票 交易异常波动的情形｡ 经核实，公司目前生产经营活动一切正常，未发生重大变化。公司第一大股东 VeriSilicon Limited发函确认，截至公告披露日，公司及第一大股东不存在应披露而未披露的重大信息。 预计截至2025年第二季度末，公司在手订单金额为30.25亿元，在手订单已连续七个季度保持高位，较 2025年第一季度末增长23.17%，再创公司历史新高。 ...

电子城公告，公司股票于2025年8月18日、8月19日、8月20日连续3个交易日内日收盘价格涨幅偏离值累 计超过20%，属于《上海证券交易所交易规则》规定的股票交易异常波动情形。经公司自查并向控股股 东征询确认，截至本公告披露日，除已披露的信息外，公司、控股股东不存在影响公司股票交易异常波 动的应披露而未披露的重大信息。公司股票价格短期内涨幅较大，敬请广大投资者注意二级市场交易风 险，审慎决策，理性投资。 ...

Core Viewpoint - The stock price of Nord New Materials Co., Ltd. experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days in August 2025, prompting regulatory scrutiny [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price rose by a cumulative 20% on August 15, 18, and 19, 2025, indicating abnormal trading behavior as per Shanghai Stock Exchange regulations [2][4]. - The stock price increased by 33.18% from August 14 to August 19, 2025, while the relevant industry index only rose by 3.99% during the same period [8]. Group 2: Financial Performance - In 2024, the company reported a revenue of 5.277 billion, a year-on-year increase of 15.44%, but incurred a net loss of 352 million [5]. - For the first quarter of 2025, the company achieved a revenue of 1.409 billion but reported a net loss of 38 million [5]. - Preliminary estimates suggest a net loss of approximately 70 million for the first half of 2025, with a net loss of around 82 million after excluding non-recurring items [5]. Group 3: Regulatory Issues - The company and its chairman, along with other executives, received a notice from the China Securities Regulatory Commission regarding suspected violations of information disclosure laws [3][9]. - The company is cooperating with the investigation and has not yet received a conclusive opinion on the matter [9]. Group 4: Management Assurance - The board of directors confirmed that there are no undisclosed significant matters that could affect stock trading, and all required disclosures have been made [12].

Core Viewpoint - The stock of Jimin Health Management Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, prompting a risk warning to investors [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price increased by 53.78% from August 13 to August 19, 2025, with significant deviations from the market and sector trends [2][7]. - The stock's closing price deviation reached a cumulative value of 20% on August 18 and 19, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange rules [3][4]. Group 2: Company Verification and Confirmation - The company conducted a self-examination and confirmed that there were no significant changes in its main business or external operating environment, and no undisclosed major matters exist [4][5]. - The company received written confirmation from its controlling shareholder and actual controller, stating that there are no undisclosed major asset restructurings, share issuances, or significant transactions [4][5]. Group 3: Financial Performance Risks - The company reported a net loss of 59.71 million yuan for the fiscal year 2024 and anticipates a net loss between 55 million yuan and 46 million yuan for the first half of 2025, indicating a decline compared to the previous year [2][7]. - The recent stock price increase is not aligned with the company's fundamental performance, suggesting a risk of short-term price correction [2][7].

Core Viewpoint - The stock of COFCO Sugar Holdings Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days in August 2025 [2][3]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly on August 15, 18, and 19, 2025, leading to a classification of abnormal trading behavior as per the Shanghai Stock Exchange regulations [2][3]. - The company confirmed that there are no undisclosed significant information affecting the stock's trading fluctuations, based on self-inspection and consultation with its controlling shareholder, COFCO Group [4][5]. Group 2: Operational and Financial Status - The company reported that its production and operational activities are normal, with no significant changes in its main business despite a more complex external operating environment [4]. - The company anticipates a decline in net profit for the first half of 2025, estimating a range of 42.384 million to 49.076 million yuan, which represents a decrease of 37.174 million to 43.866 million yuan compared to the same period last year, equating to a year-on-year decline of 43.10% to 50.86% [2][8]. Group 3: Management and Disclosure - The company and its controlling shareholder have confirmed that there are no undisclosed major matters related to the company [5]. - During the period of stock price fluctuations, there were no transactions involving the company's stock by its controlling shareholders, directors, supervisors, or senior management [6].

Core Viewpoint - The stock of Founder Technology Group Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days in August 2025 [2][3]. Group 1: Stock Trading Abnormality - The company's stock (stock code: 600601) had a cumulative closing price increase of 20% on August 15, 18, and 19, 2025, which qualifies as an abnormal trading fluctuation according to the Shanghai Stock Exchange trading rules [2][3]. - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal and external operating environment [4]. Group 2: Major Events - The company plans to implement a specific issuance of A-shares for the year 2025, which was approved at the first extraordinary general meeting of shareholders on June 27, 2025. This issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [5][6]. - As of the announcement date, the company and its controlling shareholders have no undisclosed major events that could affect the stock, such as asset restructuring or significant transactions [5][6]. Group 3: Market Sentiment and Other Information - The company has not identified any media reports or market rumors that could impact its stock price, nor is it involved in any trending concepts [6]. - During the period of abnormal stock trading, the company's directors, supervisors, senior management, and controlling shareholders did not engage in buying or selling the company's stock [7]. - The company disclosed a share reduction plan by a shareholder, intending to reduce up to 94,511,991 shares, with a reduction period from August 7 to November 6, 2025 [7].

Group 1 - The company experienced a significant stock price fluctuation, with a cumulative deviation of 35.11% over two consecutive trading days on August 18 and 19, 2025, indicating abnormal trading activity [1] - The company's board of directors conducted inquiries with major stakeholders, including the controlling shareholder and senior management, confirming no undisclosed significant information affecting stock trading [1][2] - The company has not disclosed any major matters related to its pre-restructuring process that have not been previously reported, ensuring compliance with relevant regulations [2][3] Group 2 - The company is currently undergoing a pre-restructuring process, which is a preliminary step before formal restructuring, and the outcome remains uncertain [3] - If the restructuring is successful, it could improve the company's financial structure and sustainability; however, failure could lead to bankruptcy and delisting risks [3]